Press Release Archive
-
Janssen Announces Intent Not to Enforce Patents for Darunavir in Resource-Limited SettingsPolicy Aims to Support a Sustainable Supply of Medically Acceptable Generic Darunavir in Sub-Saharan Africa (SSA) and Least Developed Countries (LDC)
-
INCRAFT™ AAA Stent-Graft System One-Year Follow-Up Data Presented At 2012 Veith SymposiumStudy Demonstrates Safety and Efficacy of New Customizable and Ultra-Low Profile Stent-Graft System for the Treatment of Abdominal Aortic Aneurysms
-
Janssen Research & Development Announces Establishment of Global Cross-Pharmaceutical Clinical Trial Investigator DatabankLilly and Merck are First to Join Janssen in this Pre-Competitive Initiative to Increase Efficiencies in Clinical Trials
-
Steering Drivers In The Right Direction, “Healthy Vision™ With Dr. Val Jones” Radio Show Offers Information, Advice About Driving In The DarkEnd of Daylight Savings Time means fewer hours of daylight; Experts talk about what happens to your eyes and on the road when it gets dark
-
Johnson & Johnson Family of Diabetes Companies Provides Diabetes Supplies to Children in Developing CountriesLifeScan, Inc. supplies one million test strips and encourages support for International Diabetes Federation’s Life for a Child program
-
New Phase 3 Findings Show STELARA® Significantly Reduced Signs And Symptoms Of Active Psoriatic ArthritisSTELARA Continued to Provide Benefit in Psoriatic Arthritis Signs and Symptomsthrough Week 52 in One Phase 3 Trial
-
Phase 3 Data Show Intravenous Golimumab Inhibited Radiographic Progression In Patients With Active Rheumatoid ArthritisPatients Receiving Intravenous Golimumab Showed Significant Improvements inSigns and Symptoms of Rheumatoid Arthritis through One Year According to New Study Findings
-
Efficacy and Safety Data from Phase 2B Trials of Janssen’s Simeprevir in Hepatitis C Patients with Advanced Fibrosis of the Liver Presented at Annual Meeting of the American Association for the Study of Liver DiseasesData from Post Hoc Analyses of the ASPIRE and PILLAR Studies in Patients with Metavir Scores of F3 and F4 Show Sustained Viral Response Compared to Placebo
-
FDA Approves New 800mg PREZISTA® (darunavir) Tablet
-
Health Care Executive, Scholar and Vice Chancellor from UCLA, Dr. A. Eugene Washington, Appointed to Johnson & Johnson Board of Directors